Piramal Pharma Solutions, a CDMO and part of Piramal Pharma Ltd., has completed the successful integrated development and manufacturing of drug substance and drug product for Brenzavvy (bexagliflozin), TheracosBio’s recently approved treatment for type 2 diabetes.   The U.S. FDA approved Brenzavvy, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, in January 2023. The FDA approval is based on results from a clinical program that evaluated the safety and efficacy of Brenzavvy in 23 clin...